N/A N=96 Arthroscopic Anterior Cruciate Ligament Reconstruction: A Comparison of Three Catheter Placement Positions
Pain, Postoperative
Primary: Pain — 24; 24; 24; 24 participants that experienced pain
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=90 A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions
Skin Diseases
Primary: To Assess the Percentage Change in Acne Lesion Swelling (Height) of the Target Lesion for 3% Benzoyl Peroxide (BPO) Gel Test Product Relative to the Vehicle Gel After 4…
N/A N=51 The I-KAN Study: Internet Insulin Education for Kansans
Type 2 Diabetes
Primary: Frequency of Hypoglycemia — 6.88 incidents per person-year
N/A N=122 Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications
Diabetes · Obesity · Weight Gain
Primary: Mean Weight — 235.22; 232.1; 235.95; 233.41 Pounds — p=<0.01
Phase 2 N=162 Trial of Poor Performance Status Patients (ToPPS)
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 2.8; 4.0; 4.8 months
N/A N=50 Evaluation of the Cook Biodesign® Nipple Reconstruction Cylinder (NRC)
Breast Cancer · Breast Reconstruction · Nipple Reconstruction
Primary: Percent Nipple Projection at 12 Months Compared to Baseline (1 Week Post-procedure) — 37.3 percentage of projection vs baseline
Phase 3 N=800 WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation
Atrial Fibrillation · Stroke
Primary: Composite of Stroke, Systemic Embolism and Cardiovascular or Unexplained Death — 2.2; 3.7 events per 100 pt yrs
Phase 2 N=36 Ursodiol in Treating Patients With Barrett Esophagus and Low-Grade Dysplasia
Barrett Esophagus · Esophageal Carcinoma
Primary: Reversal of Oxidative DNA Damage as Assessed by Changes in 8-hydroxy-2' -Deoxyguanosine (8OHdG) Immunostaining — 1.62 % of strongly/moderately stained nuclei — p=0.54
Phase 3 N=50 Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)
Major Depressive Disorder
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 49; 2 Participants
Phase 4 N=25 Safety and Tolerability of Zipsor® in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute
Pain
Primary: Safety and Tolerability of Zipsor® in Pediatric Subjects, Ages 12 to 17 Years — 12; 0; 1; 1 participants
N/A N=96 The Effect of a Nutritional Supplement on Post Prandial Glucose and Lipids in an Adult Population
Impaired Fasting Glucose
Primary: Cmax for Glucose in IFG Status Participants — 42.76; 47.40 mg/dL — p=0.0487
Phase 2 N=31 Videophone Administered Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder
Obsessive Compulsive Disorder
Primary: Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS; Scahill et al., 1997). The CY-BOCS is a 10-item Semi-structured Measure of Obsession and Compulsion Severity…
N/A N=31 Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status
Obesity · Metabolic Syndrome · Hyperuricemia
Primary: Percent Increase in Insulin-stimulated Glucose Uptake — 231; 162; NA; 156 % incr. in insulin-mediated gluc. uptake
N/A N=31 Tear Film Stability of DAILIES® AquaComfort Plus® Contact Lenses vs. MyDay® Daily Disposable Contact Lenses
Refractive Error
Primary: Mean Time Post-blink to 15% Distortion of the Projected Rings After 12 Hours of Lens Wear — 22.84; 22.87 seconds
Phase 2 N=40 Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
Primary: Progression Free Survival — 7.8; 2.8; 10.9 months — p=.08